Literature DB >> 10423325

Bioartificial liver treatment in rats with fulminant hepatic failure: effect on DNA-binding activity of liver-enriched and growth-associated transcription factors.

K S Suh1, H Lilja, Y Kamohara, S Eguchi, N Arkadopoulos, T Neuman, A A Demetriou, J Rozga.   

Abstract

BACKGROUND: We earlier described a model of fulminant hepatic failure (FHF) in the rat where partial hepatectomy is combined with induction of right liver lobe necrosis. In FHF rats, lack of regeneration of the residual liver was associated with delayed expression of HGF and HGF receptor c-met and elevated blood HGF and TGF-beta1 levels. We then found that intrasplenic hepatocyte transplantation prolonged survival in FHF rats and triggered hepatocyte proliferation in the native liver. The latter effect was associated with accelerated expression of HGF and c-met mRNA in the liver and lowering of blood HGF and TGF-beta1 levels. In the present study we show that in FHF rats, treatment with a bioartificial liver (BAL) had similar effects.
MATERIALS AND METHODS: FHF was induced in inbred Lewis rats and after 4 h, Group 1 rats were subjected to a 4-h whole blood perfusion through the BAL loaded with 3 x 10(8) microcarrier-attached syngeneic hepatocytes, whereas Group 2 control rats were treated with the BAL containing microcarriers only.
RESULTS: Compared to sham-BAL-treated rats, the test rats lived longer (28 +/- 5 vs 17 +/- 2 h; P = 0.0005), had better coagulation parameters, maintained higher body core temperature, and showed decreased plasma TGF-beta1 levels. In addition, their liver remnants were HGF positive and showed increased DNA binding of transcription factors engaged in the modulation of hepatocyte proliferation (e.g., STAT3) and liver-specific gene expression (e.g., HNF1, HNF4, C/EBP).
CONCLUSIONS: This study demonstrates that hepatocyte-based extracorporeal support not only can provide metabolic support by increasing the available functional liver mass but also is capable of modifying humoral and molecular mechanisms which are responsible for proliferation and organ-specific functions of residual hepatocytes. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423325     DOI: 10.1006/jsre.1999.5669

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  The development of a new bioartificial liver and its application in 12 acute liver failure patients.

Authors:  Yi-Tao Ding; Yu-Dong Qiu; Zhong Chen; Qing-Xiang Xu; He-Yuan Zhang; Qing Tang; De-Cai Yu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure.

Authors:  Harvey S Chen; Dong Jin Joo; Mohammed Shaheen; Yi Li; Yujia Wang; Jian Yang; Clara T Nicolas; Kelly Predmore; Bruce Amiot; Gregory Michalak; Taofic Mounajjed; Jeff Fidler; Walter K Kremers; Scott L Nyberg
Journal:  Hepatology       Date:  2018-12-27       Impact factor: 17.425

3.  Porcine acute liver failure model established by two-phase surgery and treated with hollow fiber bioartificial liver support system.

Authors:  Yi Gao; Ning Mu; Xiao-Ping Xu; Yan Wang
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

4.  Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.

Authors:  Achilles A Demetriou; Robert S Brown; Ronald W Busuttil; Jeffrey Fair; Brendan M McGuire; Philip Rosenthal; Jan Schulte Am Esch; Jan Lerut; Scott L Nyberg; Mauro Salizzoni; Elizabeth A Fagan; Bernard de Hemptinne; Christoph E Broelsch; Maurizio Muraca; Joan Manuel Salmeron; John M Rabkin; Herold J Metselaar; Daniel Pratt; Manuel De La Mata; Lawrence P McChesney; Gregory T Everson; Philip T Lavin; Anthony C Stevens; Zorina Pitkin; Barry A Solomon
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

Review 5.  Clinical application of bioartificial liver support systems.

Authors:  Maarten Paul van de Kerkhove; Ruurdtje Hoekstra; Robert A F M Chamuleau; Thomas M van Gulik
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

6.  Construction of IL-2 gene-modified human hepatocyte and its cultivation with microcarrier.

Authors:  Nan-Hong Tang; Yian-Ling Chen; Xiao-Qian Wang; Xiu-Jin Li; Feng-Zhi Yin; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

7.  Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure.

Authors:  Geert A A Nibourg; Robert A F M Chamuleau; Tessa V van der Hoeven; Martinus A W Maas; An F C Ruiter; Wouter H Lamers; Ronald P J Oude Elferink; Thomas M van Gulik; Ruurdtje Hoekstra
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.